An open-label study of LentiGlobin BB305 in paediatric patients with beta thalassaemia major

Trial Profile

An open-label study of LentiGlobin BB305 in paediatric patients with beta thalassaemia major

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs BB305 beta-globin gene therapy bluebird bio (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2015 According to bluebird bio media release, NIH RAC review of HGB-207 (see 700257159) and HGB-208 study protocols in adult and adolescent patients with beta-thalassemia major and pediatric patients with beta-thalassemia major, respectively have been completed.
    • 21 May 2015 New trial record
    • 19 May 2015 bluebird bio plans to pursue conditional and accelerated registration strategies in EU and US, respectively. Company filed clinical study protocol for HGB-208 study with the NIH Recombinant DNA Advisory Committee (RAC) and was notified that HGB-208 study protocol is scheduled for public review on June 9, 2015. The data from this and three other studies (HGB-205, HGB-207 and HGB-208) will support the Biologics License Application (BLA) submission for LentiGlobin BB305.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top